Phenylthiazoles with potent & optimum selectivity toward Clostridium difficile

Area of Science:

• Medicinal Chemistry
• Microbiology
• Antimicrobial Drug Discovery

Background:

• Clostridioides difficile (C. diff) poses a significant global health threat due to high mortality and morbidity.
• Antibiotic resistance and disruption of the gut microbiome necessitate the development of alternative antibiotics with minimal impact on normal gut flora.

Purpose of the Study:

• To synthesize and evaluate novel compounds for selective targeting of Clostridioides difficile.
• To identify an effective alternative antibiotic with a favorable safety profile and minimal disruption to the human gut microbiome.

Main Methods:

• Chemical synthesis involving cyclization of an aminoguanidine head to a thiazole nucleus.
• Determination of Minimum Inhibitory Concentration (MIC) values against multiple C. diff strains.
• Assessment of inhibitory effects on nine strains of normal human gut microbiota.
• Evaluation of compound safety using HRT-18 and Vero cell lines.

Main Results:

• The most promising compound, designated as compound 5, demonstrated significantly higher efficiency against six C. diff strains compared to vancomycin and metronidazole, with MIC values as low as 0.030 μg mL⁻¹.
• Compound 5 exhibited no inhibition against nine tested strains of normal human gut microbiota at concentrations above 64 μg mL⁻¹, outperforming vancomycin and metronidazole.
• Compound 5 displayed a high safety profile in cytotoxicity assays using HRT-18 and Vero cell lines.

Conclusions:

• The novel synthetic compound 5 exhibits potent and selective activity against Clostridioides difficile.
• Compound 5 represents a promising candidate for a new antibiotic therapy due to its efficacy, selectivity, and favorable safety profile.
• This compound offers a potential solution for combating C. diff infections while preserving gut microbiome integrity.